Design, synthesis, and characterization of peptide-based rab geranylgeranyl transferase inhibitors

Journal of Medicinal Chemistry

Volumn 52, Issue 24, 2009, Pages 8025-8037

  Tan, Kui Thong ^a   Guiu Rozas, Ester ^a   Bon, Robin S ^a   Guo, Zhong ^a   Delon, Christine ^a   Wetzel, Stefan ^a   Arndt, Sabine ^a   Alexandrov, Kirill ^a,b   Waldmann, Herbert ^a   Goody, Roger S ^a   Wu, Yao Wen ^a   Blankenfeldt, Wulf ^a  

^a MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY   (Germany)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTICINNAMIN E; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAB GERANYLGERANYLTRANSFERASE; RAB GERANYLGERANYLTRANSFERASE INHIBITOR; TRANSFERASE; TRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYTOTOXICITY; DISSOCIATION CONSTANT; DRUG ACTIVITY; DRUG DESIGN; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME SPECIFICITY; IC 50; ISOPRENYLATION; NONHUMAN; SOLID PHASE SYNTHESIS; STRUCTURE ACTIVITY RELATION;

ALKYL AND ARYL TRANSFERASES; ANIMALS; CATALYTIC DOMAIN; CERCOPITHECUS AETHIOPS; COS CELLS; ENZYME INHIBITORS; KINETICS; MODELS, MOLECULAR; OLIGOPEPTIDES; PEPTIDE LIBRARY; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 73249143294     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm901117d     Document Type: Article

References (51)

1. Leung, K. F.; Baron, R.; Seabra, M. C. Thematic review series: lipid posttranslational modifications. geranylgeranylation of Rab GTPases. J. Lipid Res. 2006, 47, 467-475.
2. Zerial, M.; McBride, H. Rab proteins as membrane organizers. Nat. Rev. Mol. Cell Biol. 2001, 2, 107-117.
3. Miaczynska, M.; Christoforidis, S.; Giner, A.; Shevchenko, A.; Uttenweiler-Joseph, S.; Habermann, B.; Wilm, M.; Parton, R. G.; Zerial, M. APPL proteins link Rab5 to nuclear signal transduction via an endosomal compartment. Cell 2004, 116, 445-456.
4. Alexandrov, K.; Horiuchi, H.; Steele-Mortimer, O.; Seabra, M. C.; Zerial, M. Rab escort protein-1 is a multifunctional protein that accompanies newly prenylated rab proteins to their target membranes. EMBO J. 1994, 13, 5262-5273.
5. Guo, Z.; Wu, Y. W.; Das, D.; Delon, C.; Cramer, J.; Yu, S.; Thuns, S.; Lupilova, N.; Waldmann, H.; Brunsveld, L.; Goody, R. S.; Alexandrov, K.; Blankenfeldt, W. Structures of RabGGTasesubstrate/product complexes provide insights into the evolution of protein prenylation. EMBO J. 2008, 27, 2444-2456.
6. Pylypenko, O.; Rak, A.; Reents, R.; Niculae, A.; Sidorovitch, V.; Cioaca, M. D.; Bessolitsyna, E.; Thoma, N. H.; Waldmann, H.; Schlichting, I.; Goody, R. S.; Alexandrov, K. Structure of Rab escort protein-1 in complex with Rab geranylgeranyltransferase. Mol. Cell 2003, 11, 483-494.
7. Croizet-Berger, K.; Daumerie, C.; Couvreur, M.; Courtoy, P. J.; van den Hove, M. F. The endocytic catalysts, Rab5a and Rab7, are tandem regulators of thyroid hormone production. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 8277-8282.
8. He, H.; Dai, F.; Yu, L.; She, X.; Zhao, Y.; Jiang, J.; Chen, X.; Zhao, S. Identification and characterization of nine novel human small GTPases showing variable expressions in liver cancer tissues. Gene Expression 2002, 10, 231-242.
9. Cheng, K. W.; Lahad, J. P.; Kuo, W. L.; Lapuk, A.; Yamada, K.; Auersperg, N.; Liu, J.; Smith-McCune, K.; Lu, K. H.; Fishman, D.; Gray, J. W.; Mills, G. B. The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat. Med. 2004, 10, 1251-1256.
10. Cheng, K. W.; Lahad, J. P.; Gray, J. W.; Mills, G. B. Emerging role of RAB GTPases in cancer and human disease. Cancer Res. 2005, 65, 2516-2519.
11. Gonzalez-Santiago, L.; Alfonso, P.; Suarez, Y.; Nunez, A.; Garcia-Fernandez, L. F.; Alvarez, E.; Munoz, A.; Casal, J. I. Proteomic analysis of the resistance to aplidin in human cancer cells. J. Proteome Res. 2007, 6, 1286-1294.
12. Lackner, M. R.; Kindt, R. M.; Carroll, P. M.; Brown, K.; Cancilla, M. R.; Chen, C.; de Silva, H.; Franke, Y.; Guan, B.; Heuer, T.; Hung, T.; Keegan, K.; Lee, J. M.; Manne, V.; O'Brien, C.; Parry, D.; Perez-Villar, J. J.; Reddy, R. K.; Xiao, H.; Zhan, H.; Cockett, M.; Plowman, G.; Fitzgerald, K.; Costa, M.; Ross-Macdonald, P. Chemical genetics identifies Rab geranylgeranyl transferase as an apoptotic target of farnesyl transferase inhibitors. Cancer Cell 2005, 7, 325-336.
13. Konstantinopoulos, P. A.; Karamouzis, M. V.; Papavassiliou, A. G. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat. Rev. Drug Discovery 2007, 6, 541-555.
14. Karaman, M. W.; Herrgard, S.; Treiber, D. K.; Gallant, P.; Atteridge, C. E.; Campbell, B. T.; Chan, K. W.; Ciceri, P.; Davis, M. I.; Edeen, P. T.; Faraoni, R.; Floyd, M.; Hunt, J. P.; Lockhart, D. J.; Milanov, Z. V.; Morrison, M. J.; Pallares, G.; Patel, H. K.; Pritchard, S.; Wodicka, L. M.; Zarrinkar, P. P. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 2008, 26, 127-132.
15. Sebti, S. M.; Hamilton, A. D. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene 2000, 19, 6584-6593.
16. Gibbs, R. A.; Zahn, T. J.; Sebolt-Leopold, J. S. Nonpeptidic prenyltransferase inhibitors: diverse structural classes and surprising anti-cancer mechanisms. Curr. Med. Chem. 2001, 8, 1437-1465.
17. El Oualid, F.; Cohen, L. H.; van der Marel, G. A.; Overhand, M. Inhibitors of protein: geranylgeranyl transferases. Curr. Med. Chem. 2006, 13, 2385-2427.
18. Bell, I. M. Inhibitors of farnesyltransferase: a rational approach to cancer chemotherapy? J. Med. Chem. 2004, 47, 1869-1878.
19. Baron, R. A.; Tavare, R.; Figueiredo, A. C.; Blazewska, K. M.; Kashemirov, B. A.; McKenna, C. E.; Ebetino, F. H.; Taylor, A.; Rogers, M. J.; Coxon, F. P.; Seabra, M. C. Phosphonocarboxylates inhibit the second geranylgeranyl addition by Rab geranylgeranyl transferase. J. Biol. Chem. 2009, 284, 6861-6868.
20. Coxon, F. P.; Helfrich, M. H.; Van't Hof, R.; Sebti, S.; Ralston, S. H.; Hamilton, A.; Rogers, M. J. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J. Bone Miner. Res. 2000, 15, 1467-1476.
21. Coxon, F. P.; Helfrich, M. H.; Larijani, B.; Muzylak, M.; Dunford, J. E.; Marshall, D.; McKinnon, A. D.; Nesbitt, S. A.; Horton, M. A.; Seabra, M. C.; Ebetino, F. H.; Rogers, M. J. Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages. J. Biol. Chem. 2001, 276, 48213-48222.
22. Ren, Z.; Elson, C. E.; Gould, M. N. Inhibition of type I and type II geranylgeranyl-protein transferases by the monoterpene perillyl alcohol in NIH3T3 cells. Biochem. Pharmacol. 1997, 54, 113-120.
23. Castellano, S.; Fiji, H. D. G.; Kinderman, S. S.; Watanabe, M.; de Leon, P.; Tamanoi, F.; Kwon, O. Small-molecule inhibitors of protein geranylgeranyltransferase type I. J. Am. Chem. Soc. 2007, 129, 5843-5845.
24. Watanabe, M.; Fiji, H. D.; Guo, L.; Chan, L.; Kinderman, S. S.; Slamon, D. J.; Kwon, O.; Tamanoi, F. Inhibitors of protein geranylgeranyltransferase I and Rab geranylgeranyltransferase identified from a library of allenoate-derived compounds. J. Biol. Chem. 2008, 283, 9571-9579.
25. Nguyen, U. T.; Guo, Z.; Delon, C.; Wu, Y.; Deraeve, C.; Franzel, B.; Bon, R. S.; Blankenfeldt, W.; Goody, R. S.; Waldmann, H.; Wolters, D.; Alexandrov, K. Analysis of the eukaryotic prenylome by isoprenoid affinity tagging. Nat. Chem. Biol. 2009, 5, 227-235.
26. Wu, Y. W.; Goody, R. S.; Abagyan, R.; Alexandrov, K. Structure of the DisorderedCTerminus of Rab7 GTPase Induced by Binding to the Rab Geranylgeranyl Transferase Catalytic Complex Reveals the Mechanism of Rab Prenylation. J. Biol. Chem. 2009, 284, 13185-13192.
27. Breinbauer, R.; Vetter, I. R.; Waldmann, H. From protein domains to drug candidates;natural products as guiding principles in the design and synthesis of compound libraries. Angew. Chem., Int. Ed. 2002, 41, 2879-2890.
28. Newman, D. J.; Cragg, G. M. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod. 2007, 70, 461-477.
29. Omura, S.; Van der Pyl,D.; Inokoshi, J.; Takahashi, Y.; Takeshima, H. Pepticinnamins, new farnesyl-protein transferase inhibitors produced by an actinomycete. I. Producing strain, fermentation, isolation and biological activity. J. Antibiot. 1993, 46, 222-228.
30. Shiomi, K.; Yang, H.; Inokoshi, J.; Van der Pyl, D.; Nakagawa, A.; Takeshima, H.; Omura, S. Pepticinnamins, new farnesyl-protein transferase inhibitors produced by an actinomycete. II. Structural elucidation of pepticinnamin E. J. Antibiot. 1993, 46, 229-34.
31. Guo, Z.; Wu, Y. W.; Tan, K. T.; Bon, R. S.; Guiu-Rozas, E.; Delon, C.; Nguyen, T. U.; Wetzel, S.; Arndt, S.; Goody, R. S.; Blankenfeldt, W.; Alexandrov, K.; Waldmann, H. Development of selective RabGGTase inhibitors and crystal structure of a RabGGTase-inhibitor complex. Angew. Chem., Int. Ed. 2008, 47, 3747-3750.
32. Peters, C.; Waldmann, H. Solid-phase synthesis of peptide esters employing the hydrazide linker. J. Org. Chem. 2003, 68, 6053-6055.
33. Kragol, G.; Lumbierres, M.; Palomo, J. M.; Waldmann, H. Solid-phase synthesis of lipidated peptides. Angew. Chem., Int. Ed. 2004, 43, 5839-5842.
34. Lumbierres, M.; Palomo, J. M.; Kragol, G.; Roehrs, S.; Muller, O.; Waldmann, H. Solid-phase synthesis of lipidated peptides. Chemistry 2005, 11, 7405-7415.
35. Stieber, F.; Grether, U.; Waldmann, H. An Oxidation-Labile Traceless Linker for Solid-Phase Synthesis. Angew. Chem., Int. Ed. Engl. 1999, 38, 1073-1077.
36. Stieber, F.; Grether, U.; Waldmann, H. Development of the traceless phenylhydrazide linker for solid-phase synthesis. Chemistry 2003, 9, 3270-3281.
37. Hinterding, K.; Hagenbuch, P.; Rétey, J.;Waldmann, H. Synthesis and In Vitro Evaluation of the Ras Farnesyltransferase Inhibitor Pepticinnamin E. Angew. Chem., Int. Ed. Engl. 1998, 37, 1236-1239.
38. Thutewohl, M.; Kissau, L.; Popkirova, B.; Karaguni, I. M.; Nowak, T.; Bate, M.; Kuhlmann, J.; Muller, O.; Waldmann, H. Identification of mono- and bisubstrate inhibitors of protein farnesyltransferase and inducers of apoptosis from a pepticinnamin E library. Bioorg. Med. Chem. 2003, 11, 2617-2626.
39. Thutewohl,M.;Kissau, L.; Popkirova, B.; Karaguni, I.M.;Nowak, T.; Bate, M.; Kuhlmann, J.; Muller, O.; Waldmann, H. Solid-phase synthesis and biological evaluation of a pepticinnamin E library. Angew. Chem., Int. Ed. 2002, 41, 3616-20; 3516.
40. Thutewohl, M.; Waldmann, H. Solid-phase synthesis of a pepticinnamin E library. Bioorg. Med. Chem. 2003, 11, 2591-2615.
41. Wu, Y. W.; Alexandrov, K.; Brunsveld, L. Synthesis of a fluorescent analogue of geranylgeranyl pyrophosphate and its use in a high-throughput fluorometric assay for Rab geranylgeranyltransferase. Nat. Protoc. 2007, 2, 2704-2711.
42. Long, S. B.; Casey, P. J.; Beese, L. S. Reaction path of protein farnesyltransferase at atomic resolution. Nature 2002, 419, 645-650.
43. Taylor, J. S.; Reid, T. S.; Terry, K. L.; Casey, P. J.; Beese, L. S. Structure of mammalian protein geranylgeranyltransferase type-I. EMBO J. 2003, 22, 5963-5974.
44. Dursina, B.; Reents, R.; Delon, C.; Wu, Y.; Kulharia, M.; Thutewohl, M.; Veligodsky, A.; Kalinin, A.; Evstifeev, V.; Ciobanu, D.; Szedlacsek, S. E.; Waldmann, H.; Goody, R. S.; Alexandrov, K. Identification and specificity profiling of protein prenyltransferase inhibitors using new fluorescent phosphoisoprenoids. J. Am. Chem. Soc. 2006, 128, 2822-2835.
45. Thoma, N. H.; Iakovenko, A.; Owen, D.; Scheidig, A. S.; Waldmann, H.; Goody, R. S.; Alexandrov, K. Phosphoisoprenoid binding specificity of geranylgeranyltransferase type II. Biochemistry 2000, 39, 12043-12052.
46. Wu, Y. W.; Waldmann, H.; Reents, R.; Ebetino, F. H.; Goody, R. S.; Alexandrov, K.Aprotein fluorescence amplifier: continuous fluorometric assay for rab geranylgeranyltransferase. ChemBioChem 2006, 7, 1859-1861.
47. Reents, R.; Wagner, M.; Schlummer, S.; Kuhlmann, J.; Waldmann, H. Synthesis and application of fluorescent ras proteins for live-cell imaging. ChemBioChem 2005, 6, 86-94.
48. Kabsch, W. Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. J. Appl. Crystallogr. 1993, 26, 795-800.
49. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr., Sect. D: Biol.Crystallogr 1997, 53, 240-255.
50. Emsley, P.; Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60, 2126-2132.
51. Schuttelkopf,A. W.; Van Aalten, D. M.PRODRG: a tool for highthroughput crystallography of protein-ligand complexes. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60, 1355-1363.